BioWorld

Sep. 22, 2005

VaxGen Reduces Celltrion Stake Via $15M Financing

VaxGen Inc. raised $15 million by selling a portion of its shares in Celltrion Inc. while still maintaining a significant stake in the joint venture. (BioWorld Today) Read More

Interim Positive Data Seen For Isotechnika's Psoriasis Drug

2005 Lasker Award Given For Chance Stem Cell Discovery

Sandoz Files Suit Against FDA For Non-Action On Omnitrope

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Sept. 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Sept. 18, 2025.

Health professional pointing stethoscope at Clinical Trial words, icons

‘Prolific’ Regeneron won’t stop with phase III FOP data drop

BioWorld

“People have some inability to focus on [Regeneron Pharmaceuticals Inc.’s] pipeline,” which stands as “the most prolific in the industry, I would dare to say,”...

The ‘molecular revolution’ driving R&D of new cancer therapeutics

BioWorld Asia

“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at...

Elderly woman holding illustration of brain with missing puzzle piece

Remynd’s REM-127 yields positive phase II data in Alzheimer’s

BioWorld

Remynd NV has turned in positive phase IIa data for a new target in Alzheimer’s disease, showing that restoring calcium homeostasis in neurons reduces levels of...